Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wynn

Showing results (101-110 of 356) with videos related to

Pageof 36
Sort By:
General Dentistry|September 10, 2011
FDA new drug approvals in 2010Richard L Wynn
General Dentistry|December 7, 2007
Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?Richard L Wynn
General Dentistry|January 1, 1996
Oral pilocarpine (Salagen)--a recently approved salivary stimulantR L Wynn
General Dentistry|September 1, 1991
Amoxicillin updateR L Wynn
General Dentistry|February 5, 2010
Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient)Richard L Wynn
General Dentistry|November 13, 2009
Antibiotic prophylaxis for all total joint replacement dental patients: where's the evidence?Richard L Wynn
The Journal of Pediatrics|December 24, 2018
Early onset and hospital acquired neonatal sepsis associated with high mortalityJames L Wynn
General Dentistry|August 8, 2008
Do Fosamax-type drugs increase the risk of osteonecrosis of the jaw for patients receiving dental implants?Richard L Wynn
General Dentistry|September 25, 2008
FDA new drug approvals in 2007Richard L Wynn
General Dentistry|May 22, 2007
Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndromeRichard L Wynn
Pageof 36

Showing results (101-110 of 356) with videos related to

Sort By:
Pageof 36
General Dentistry|September 10, 2011
FDA new drug approvals in 2010Richard L Wynn
General Dentistry|December 7, 2007
Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?Richard L Wynn
General Dentistry|January 1, 1996
Oral pilocarpine (Salagen)--a recently approved salivary stimulantR L Wynn
General Dentistry|September 1, 1991
Amoxicillin updateR L Wynn
General Dentistry|February 5, 2010
Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient)Richard L Wynn
General Dentistry|November 13, 2009
Antibiotic prophylaxis for all total joint replacement dental patients: where's the evidence?Richard L Wynn
The Journal of Pediatrics|December 24, 2018
Early onset and hospital acquired neonatal sepsis associated with high mortalityJames L Wynn
General Dentistry|August 8, 2008
Do Fosamax-type drugs increase the risk of osteonecrosis of the jaw for patients receiving dental implants?Richard L Wynn
General Dentistry|September 25, 2008
FDA new drug approvals in 2007Richard L Wynn
General Dentistry|May 22, 2007
Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndromeRichard L Wynn
Pageof 36